All In Biotech

Drug Trial Radar · NCT06847321

Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease

A Randomized, Double-Blind, Placebo-Controlled Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease

Last checked: Nov 19, 2026Latest source record: Oct 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

300

Planned (sponsor's estimate)

Start

Feb 17, 2025

Primary completion

Jan 31, 2029

Study completion Mar 15, 2029

Sponsor

Sponsor type
Industry
First posted
Feb 26, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 55 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is to test LHP588 in persons who have mild to moderate Alzheimer's disease (AD) who have shown progressive mental decline in the last year and who have P. gingivalis (Pg) infection. P. gingivalis infection has been linked to the development of dementia. LHP588 is designed to target the P. gingivalis bacterium, to potentially help to halt or slow down the progression of AD and its symptoms. A saliva test will be done to determine P. gingivalis infection. Tests for AD include standard questionnaires such as MMSE and a blood test for pTau217. Treatment will be blinded, meaning the participant and the doctor will not know if the participant is receiving LHP588 or placebo. The total time for participation in the study may be up to 64 weeks. This includes a screening period (to ensure the participant is suitable for the study and the study is suitable for the participant) of up to 12 weeks, a treatment period of up to 48 weeks, and a safety follow-up period of 4 weeks after the last dose of the study drug to check the participant's overall health. Treatment is a once-a-day capsule. Caregiver participation is required. The study requires the participant to visit the study center (with the caregiver) at least 20 times within 64 weeks (this does not include any unplanned visits that may be recommended by the study doctor). In addition, the study doctor or clinic staff will contact the participant via phone at least 1 time.

Conditions

  • Alzheimer Disease
  • Alzheimer Disease Due to P. Gingivalis

Interventions

  • LHP588Drug

    25 mg, once daily

  • LHP588Drug

    50 mg, once daily

  • Placebo DrugDrug

    Placebo, once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in ADAS-Cog11Time frame: 40 - 48 weeks

Locations

39 sites in 1 country. Site status is shown where the registry gives one.

  • Banner Alzheimer's Institute

    Phoenix, Arizona · Recruiting

  • Barrow Neurological Institute

    Phoenix, Arizona · Recruiting

  • Clinical Endpoints

    Scottsdale, Arizona · Recruiting

  • Esperanza Clinical

    Murrieta, California · Recruiting

  • Oakland Clinical Research

    Oakland, California · Recruiting

  • ATP Clinical Research, Inc.

    Orange, California · Recruiting

  • Riverside Clinical Research

    Riverside, California · Recruiting

  • CenExel Sherman Oaks

    Sherman Oaks, California · Recruiting

  • CenExel Denver, CO

    Englewood, Colorado · Recruiting

  • JEM Research Institute

    Atlantis, Florida · Recruiting

  • Brain Matters Research

    Delray Beach, Florida · Recruiting

  • Neuropsychiatric Research Center of Southwest Florida

    Fort Myers, Florida · Recruiting

  • Conquest Research - Lake Nona

    Orlando, Florida · Recruiting

  • Anchor Neuroscience

    Pensacola, Florida · Active not recruiting

  • Progressive Medical Research

    Port Orange, Florida · Recruiting

  • Alzheimer's Research and Treatment Center - Stuart

    Stuart, Florida · Recruiting

  • Alzheimer's Research and Treatment Center - Wellington

    Wellington, Florida · Recruiting

  • Columbus Memory Center

    Columbus, Georgia · Recruiting

  • Center for Advanced Research & Education Flourish-Gainesville

    Gainsville, Georgia · Recruiting

  • Ascension via Christi Research

    Wichita, Kansas · Recruiting

  • Tandem Clinical Research - Metairie

    Metairie, Louisiana · Recruiting

  • Headlands PharmaSite

    Pikesville, Maryland · Recruiting

  • Adams Clinical Boston

    Boston, Massachusetts · Recruiting

  • Headlands Research-EMA

    Plymouth, Massachusetts · Recruiting

  • Adams Clinical Watertown

    Watertown, Massachusetts · Recruiting

  • Neurological Research Center - Hattiesburg Clinic

    Hattiesburg, Mississippi · Recruiting

  • Clinical Research Professionals - Headlands

    Chesterfield, Missouri · Recruiting

  • CenExel Research - Toms River

    Toms River, New Jersey · Recruiting

  • IMA Evaluations

    Albuquerque, New Mexico · Recruiting

  • Alzheimer's Disease Research Center

    Albany, New York · Recruiting

  • Adams Clinic Harlem

    New York, New York · Recruiting

  • NDx Clinical Research

    Dayton, Ohio · Recruiting

  • Summitt Research

    Portland, Oregon · Recruiting

  • K2 Medical Research Nashville LLC

    Nashville, Tennessee · Recruiting

  • Kerwin Research Center, LLC - Oak Cliff

    Dallas, Texas · Recruiting

  • Kerwin Research Center, LLC in Texas

    Dallas, Texas · Recruiting

  • University of Virginia Adult Neurology

    Charlottesville, Virginia · Recruiting

  • Re-Cognition Health Fairfax

    Fairfax, Virginia · Active not recruiting

  • Northwest Clinical Research Center

    Bellevue, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.